Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm
1University of Michigan, Ann Arbor, MI, USA. gkhan@umich.edu
Background:
Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappaB inhibition.
Objective:
This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies.
Methods:
A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review.
Results/Conclusions:
Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and II clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Affecting Factors
Complexation Equilibria: The Chelate Effect
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
EDTA: Chemistry and Properties


